“We’ll treat people with proprietary therapy, proprietary compounds, and well trained staff in a specifically designed clinical environment,” Awakn Life Sciences CEO Anthony Tennyson said.
Awakn Life Sciences CEO Anthony Tennyson believes the company is at the cutting edge of taking a revolutionary approach to treating one of the single biggest unmet medical needs of our time.
Awakn Life Sciences (NEO:AWAKN,OTCQB: AWKNF) is currently developing compounds and therapies delivered by trained therapists at their wholly-owned clinical environments to treat both substance and behavior addiction.
This CEO Interview article is brought to you by:
Awakn Life Sciences (NEO:AWAKN,OTCQB: AWKNF) - is a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat addiction.Send me an Investor Kit
“That is exactly what we’re doing in London and what we’ll be doing in Bristol and Manchester as we open up our first three of 20 clinics in the UK this year. We’ll treat people with proprietary therapy, proprietary compounds, and well trained staff in a specifically designed clinical environment,” Tennyson said.
The company recently announced a 10-year lease to open Awakn Clinics London while initiating the first-ever study investigating ketamine in gambling addiction.
Tennyson also added that they’re taking a radical approach to develop a psychedelics package to better treat addiction.
“Psychedelic assisted psychotherapy is different,...
Read Full Story: https://investingnews.com/ceo-interviews/awakn-life-sciences-ceo-anthony-tennyson/
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.